Amneal Pharmaceuticals, Inc. (AMRX) FY2026 YTD Q2 P&L / Income Statement

Amneal Pharmaceuticals, Inc. (AMRX) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenue

1,518,716,000 US dollars

Cost of goods sold

864,095,000 US dollars

Gross profit

654,621,000 US dollars

Operating costs, net of other operating items (calculated)

383,080,000 US dollars

Operating income

271,541,000 US dollars

Total other expense, net

negative 120,375,000 US dollars

Income before income taxes

151,166,000 US dollars

Provision for income taxes

3,552,000 US dollars

Net income

147,614,000 US dollars

Affordable Medicines

913,150,000 US dollars

Specialty

282,560,000 US dollars

AvKARE

323,006,000 US dollars

Selling, general and administrative

287,582,000 US dollars

Research and development

77,400,000 US dollars

Intellectual property legal development expenses

3,629,000 US dollars

Restructuring and other charges

1,204,000 US dollars

Acquisition costs

12,753,000 US dollars

Other operating income

negative 8,239,000 US dollars

Charges (credit) related to legal matters, net

8,751,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to Amneal Pharmaceuticals, Inc.: $119.92 M; to noncontrolling interests: $27.70 M.